EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression

Jonas Saal, Markus Eckstein, Manuel Ritter, Peter Brossart, Michael Hölzel, Viktor Grünwald, Niklas Klümper

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2024.115163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Jonas Saal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn (UKB), Germany; Institute of Experimental Onc…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors, Disease Progression. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, German Cancer Aid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmune Checkpoint InhibitorsDisease ProgressionHumansPrognosisMaleFemaleImmunotherapyAgedMiddle AgedCarcinoma, Renal CellKidney NeoplasmsClinical Decision-MakingAntibodies, Monoclonal, HumanizedBiomarkers, TumorC-Reactive Protein

Stichwörter der Autor:innen

BiomarkersImmunotherapyLung cancerRenal cell carcinomaUrothelial cancer

Substanzen

Immune Checkpoint InhibitorsatezolizumabAntibodies, Monoclonal, HumanizedBiomarkers, TumorC-Reactive Protein

Autor:innen und Institutionen

  • Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn (UKB), Germany; Institute of Experimental Oncology, University Hospital Bonn (UKB), Bonn, Germany; Center for Integ…
  • Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Univer…
  • Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany; Department of Urology, University Hospital Bonn (UKB), Bonn, Germany.
  • Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn (UKB), Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
  • Institute of Experimental Oncology, University Hospital Bonn (UKB), Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
  • Department for Urology University Hospital Essen, Germany; Department for Medical Oncology, University Hospital Essen, Germany.

Förderung

  • University Hospital Bonn
  • Rheinische Friedrich-Wilhelms-Universität Bonn
  • German Cancer Aid

Zitieren

APA

Saal, J., Eckstein, M., Ritter, M., Brossart, P., Hölzel, M., Grünwald, V., & Klümper, N. (2025). The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115163

Vancouver

Saal J, Eckstein M, Ritter M, Brossart P, Hölzel M, Grünwald V, et al. The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2024.115163

BibTeX
@article{Saal2025,
  author = {Saal, Jonas and Eckstein, Markus and Ritter, Manuel and Brossart, Peter and Hölzel, Michael and Grünwald, Viktor and Klümper, Niklas},
  title = {The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2024.115163}
}
Kostenlos starten →